Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30363101 | 1.00 | GPR119 (0.47) | GPR119PDE10ANR1H2CKS1BSKP1 | |
| SCHEMBL22773670 | 1.00 | GPR119 (0.47) | GPR119PDE10ANR1H2CKS1BSKP1 | |
| SCHEMBL22796092 | 1.00 | GPR119 (0.47) | GPR119PDE10ANR1H2CKS1BSKP1 | |
| SCHEMBL4724234 | 0.83 | CKS1B (0.57) | GPR119CKS1BSKP1SKP2POLB | |
| SCHEMBL30394181 | 0.83 | CKS1B (0.57) | GPR119CKS1BSKP1SKP2POLB | |
| SCHEMBL3485544 | 0.83 | GPR119 (0.69) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL20070883 | 0.82 | RET (0.52) | GPR119CKS1BSKP1SKP2JAK1 | |
| SCHEMBL29566277 | 0.82 | RET (0.52) | GPR119CKS1BSKP1SKP2JAK1 | |
| SCHEMBL2065083 | 0.81 | GPR119 (0.46) | GPR119PDE10ANR1H2CKS1BSKP1 | |
| SCHEMBL653986 | 0.81 | CHRNB4 (0.48) | GPR119PDE10ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2022-07-14 | — | — | US | disclosed |
| WO-2020248972-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | RET, BRAF, ROR1 | GPR119 2139/4885PDE10A 932/4885NR1H2 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.